IL187085A0 - Combination therapy comprising diaryl ureas for treating diseases - Google Patents
Combination therapy comprising diaryl ureas for treating diseasesInfo
- Publication number
- IL187085A0 IL187085A0 IL187085A IL18708507A IL187085A0 IL 187085 A0 IL187085 A0 IL 187085A0 IL 187085 A IL187085 A IL 187085A IL 18708507 A IL18708507 A IL 18708507A IL 187085 A0 IL187085 A0 IL 187085A0
- Authority
- IL
- Israel
- Prior art keywords
- combination therapy
- treating diseases
- diaryl ureas
- diaryl
- ureas
- Prior art date
Links
- 235000013877 carbamide Nutrition 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- -1 diaryl ureas Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05011478 | 2005-05-27 | ||
| EP05011475 | 2005-05-27 | ||
| EP05011476 | 2005-05-27 | ||
| PCT/EP2006/004523 WO2006125539A2 (en) | 2005-05-27 | 2006-05-13 | Combination therapy comprising diaryl ureas for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL187085A0 true IL187085A0 (en) | 2008-08-07 |
Family
ID=37052960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL187085A IL187085A0 (en) | 2005-05-27 | 2007-11-01 | Combination therapy comprising diaryl ureas for treating diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090306020A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1888065A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008545670A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080012902A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006251428A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0610090A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2609387A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL187085A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007014920A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006125539A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| ES2425739T3 (es) | 2002-02-11 | 2013-10-17 | Bayer Healthcare Llc | Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| ES2305808T3 (es) | 2003-05-20 | 2008-11-01 | Bayer Healthcare Llc | Diarilureas con actividad inhibidora de quinasas. |
| BRPI0412219B8 (pt) | 2003-07-23 | 2021-07-27 | Bayer Healthcare Llc | compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos |
| US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| CN104688697A (zh) * | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| TW200835507A (en) * | 2006-12-05 | 2008-09-01 | Vioquest Pharmaceuticals Inc | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| EP2129376B1 (en) | 2007-01-19 | 2013-07-24 | Bayer HealthCare LLC | Treatment of cancers with acquired resistance to KIT inhibitors |
| US7947723B2 (en) | 2008-02-01 | 2011-05-24 | Spelman College | Synthesis and anti-proliferative effect of benzimidazole derivatives |
| CN101998944B (zh) * | 2008-04-09 | 2014-09-03 | 陶氏环球技术公司 | 用于回收二氯代醇的多级方法和设备 |
| TW201012467A (en) * | 2008-09-16 | 2010-04-01 | Taiho Pharmaceutical Co Ltd | Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid |
| US20120046333A1 (en) * | 2009-04-09 | 2012-02-23 | Oncothyreon Incorporated | Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| CA2785738A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
| ES2385276B1 (es) * | 2010-02-25 | 2013-07-05 | Universidad Del País Vasco | Compuestos para el tratamiento de alzheimer. |
| WO2012012404A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| MX394252B (es) | 2013-12-20 | 2025-03-21 | Biomed Valley Discoveries Inc | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf |
| CN114751899B (zh) * | 2022-04-24 | 2024-03-29 | 贵州医科大学 | 一种二芳基脲类mTOR激酶抑制剂及其药物组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5378725A (en) * | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
| EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ES2425739T3 (es) * | 2002-02-11 | 2013-10-17 | Bayer Healthcare Llc | Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal |
| JP4394959B2 (ja) * | 2002-04-08 | 2010-01-06 | メルク エンド カムパニー インコーポレーテッド | Ａｋｔ活性の阻害剤 |
| BRPI0412219B8 (pt) * | 2003-07-23 | 2021-07-27 | Bayer Healthcare Llc | compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos |
| WO2005089443A2 (en) * | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
| ATE517901T1 (de) * | 2004-09-06 | 2011-08-15 | Bayer Schering Pharma Ag | Pyrazolopyrimidine als hemmer der proteinkinase b (akt) |
-
2006
- 2006-05-13 JP JP2008512729A patent/JP2008545670A/ja active Pending
- 2006-05-13 WO PCT/EP2006/004523 patent/WO2006125539A2/en not_active Ceased
- 2006-05-13 CA CA002609387A patent/CA2609387A1/en not_active Abandoned
- 2006-05-13 BR BRPI0610090-2A patent/BRPI0610090A2/pt not_active Application Discontinuation
- 2006-05-13 MX MX2007014920A patent/MX2007014920A/es not_active Application Discontinuation
- 2006-05-13 KR KR1020077027599A patent/KR20080012902A/ko not_active Withdrawn
- 2006-05-13 US US11/920,952 patent/US20090306020A1/en not_active Abandoned
- 2006-05-13 AU AU2006251428A patent/AU2006251428A1/en not_active Abandoned
- 2006-05-13 EP EP06761913A patent/EP1888065A2/en not_active Withdrawn
-
2007
- 2007-11-01 IL IL187085A patent/IL187085A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0610090A2 (pt) | 2008-12-09 |
| EP1888065A2 (en) | 2008-02-20 |
| WO2006125539A2 (en) | 2006-11-30 |
| WO2006125539A3 (en) | 2007-03-08 |
| AU2006251428A1 (en) | 2006-11-30 |
| JP2008545670A (ja) | 2008-12-18 |
| KR20080012902A (ko) | 2008-02-12 |
| MX2007014920A (es) | 2008-04-09 |
| CA2609387A1 (en) | 2006-11-30 |
| US20090306020A1 (en) | 2009-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL187085A0 (en) | Combination therapy comprising diaryl ureas for treating diseases | |
| IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
| ZA200805877B (en) | Pyridiazinone derivatives for tumour treatment | |
| IL188430A0 (en) | Treatment of tumors | |
| ZA200709620B (en) | Methods for treating drug resistant cancer | |
| SI2422786T1 (sl) | Nove farmacevtske kombinacije za zdravljenje respiratornih obolenj | |
| IL185444A0 (en) | Novel drugs for treating respiratory diseases | |
| IL183520A0 (en) | Preventive or therapeutic agent for sleep disorder | |
| PT1830847E (pt) | Tratamento para o cancro | |
| IL178920A0 (en) | Treatment for pancreatic cancer | |
| ZA200810199B (en) | Rinse-off therapeutic agents for treating skin | |
| GB0428187D0 (en) | Cancer treatment | |
| GB0413346D0 (en) | Treating cancer | |
| EP1867640A4 (en) | MEANS FOR TREATING SOLID TUMORS | |
| IL187792A0 (en) | 4-anilino-3-quinolinecarbonitriles for the treatment of cancer | |
| IL226362A0 (en) | compounds, and methods for treating cancer | |
| GB0517387D0 (en) | Combinations for the treatment of cancer | |
| ZA200805522B (en) | Dioxoiane dérivates for the treatment of cancer | |
| EP1890711A4 (en) | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES | |
| GB0425854D0 (en) | Therapeutic treatment | |
| EP1942909A4 (en) | METHODS OF TREATING RESPIRATORY DISORDERS | |
| GB0525535D0 (en) | Tumour treatment | |
| EP1719514A4 (en) | MEDICAMENT FOR TREATING PAIN | |
| GB0408752D0 (en) | Therapeutic treatment | |
| GB0404675D0 (en) | Cancer treatment |